Protease-Activated Receptors

Updated: 2026-08-30

Overview

Peroxisome Proliferator-Activated Receptors (PPARs) are a group of nuclear receptor proteins that function as transcription factors, modulating gene expression in response to ligands such as fatty acids and synthetic compounds. Discovered in the 1990s, PPARs are pivotal in regulating metabolic pathways, including lipid and glucose metabolism, and are implicated in diseases like diabetes and obesity. There are three subtypes: PPAR-α, PPAR-γ, and PPAR-β/δ, each with distinct tissue distributions and functions. PPAR-α is abundant in the liver and heart, PPAR-γ in adipose tissue, and PPAR-β/δ ubiquitously. Their activation influences cellular differentiation, inflammation, and energy homeostasis, making them targets for drug development.

Physical and Chemical Properties

PPARs are proteins with molecular weights ranging from 50–60 kDa, depending on the subtype and post-translational modifications. They consist of modular domains: a DNA-binding domain (DBD) and a ligand-binding domain (LBD), which undergoes conformational changes upon ligand binding to initiate transcription. While PPARs themselves are not small molecules, their ligands (e.g., fibrates for PPAR-α, thiazolidinediones for PPAR-γ) are chemically diverse. These ligands typically exhibit high affinity (nM to μM range) and specificity for their respective PPAR subtypes, influencing downstream gene expression profiles.

Main Applications

PPARs are critical in pharmaceuticals, particularly for metabolic disorders. PPAR-γ agonists like pioglitazone are used to treat type 2 diabetes by enhancing insulin sensitivity. PPAR-α agonists (e.g., fenofibrate) lower triglycerides and are prescribed for dyslipidemia. Beyond therapeutics, PPARs are tools in research to study metabolic syndromes, inflammation, and cancer. Their role in adipogenesis makes them valuable in obesity research, while their anti-inflammatory effects are explored for neurodegenerative and cardiovascular diseases.

Safety and Storage

As proteins, PPARs and their recombinant forms require storage at –20°C or –80°C in glycerol-containing buffers to prevent denaturation. Lyophilized preparations should be reconstituted with sterile, nuclease-free water. Handling requires standard biosafety protocols: use gloves, avoid repeated freeze-thaw cycles, and store aliquots to minimize degradation. Ligands (e.g., rosiglitazone) may have specific hazards; consult SDS for toxicity and disposal guidelines.

B2B Procurement Guide

When sourcing PPAR-related reagents, prioritize suppliers with COA (Certificate of Analysis) for purity (e.g., ≥95% by SDS-PAGE) and bioactivity validation (e.g., luciferase reporter assays). For ligands, confirm enantiomeric purity if applicable. Bulk orders (e.g., for drug development) may negotiate pricing; academic researchers often purchase smaller quantities. Lead times vary—recombinant proteins may require 4–6 weeks for custom production. Verify cold-chain logistics for temperature-sensitive items.